Co-Inventors
Jahrling, Peter
Bennett, Ryan
Innovating the landscape of Ebola virus treatment, this technology harnesses the potential of small molecules, particularly Sangivanycin and its analogs, as promising therapeutic agents. Addressing the current gap in Ebola treatment options, which primarily rely on antibodies, vaccines, or RNAi, this breakthrough offers the prospect of drug-like small molecule oral or injectable treatments. With the swift progression of Ebola, where acquired immunity through vaccination proves time-consuming, this innovation carries immense significance. It not only presents the possibility of fast-acting treatments with therapeutic or curative potential but also plays a pivotal role in delaying the disease's progression, allowing sufficient time for natural or vaccine-based acquired immunity to develop. Presented at the III International Conference on Clinical Sciences and Drug Discovery (CSDD-2017), this technology marks a noteworthy stride in the quest to combat Ebola effectively.
Commercial Applications
The competitive potential of this technology extends beyond Ebola treatment. Its utilization of small molecules like Sangivanycin and analogs opens the door to broader applications in antiviral therapy. These compounds could be explored as treatments for various RNA viruses, potentially offering new solutions for viral infections beyond Ebola. Additionally, the rapid action and oral/injectable delivery capabilities make this technology adaptable for addressing other fast-progressing diseases, enhancing its competitive edge in the field of antiviral therapeutics.
Competitive Advantages
The competitive advantages of this technology stem from its unique approach to Ebola treatment. Unlike conventional methods like antibodies or vaccines, it leverages small molecules, particularly Sangivanycin and its analogs, offering the potential for oral or injectable treatments. This innovation's rapid action capability is especially advantageous in dealing with the virus's fast progression, providing a more timely therapeutic response. By slowing down the disease's advance, it complements natural and vaccine-based immunity strategies, making it a valuable addition to the Ebola treatment arsenal.
